PDL BioPharma finalises sale of cardiovascular products to EKR Therapeutics
c Cardene SR and new formulations of Cardene in development, as well as Retavase (reteplase) and the development product ularitide, to EKR Therapeutics, Inc. for $85 million in cash at closing, up to an additional $85 million in development and sales milestones, as well as royalties.
PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering and developing innovative therapies for severe or life-threatening illnesses.